TG Therapeutics Stock News

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Presid

TG Therapeutics (TGTX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.28 per share a year ago.

Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET

TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023, with positive market feedback and significant revenue. The company has strong barriers to entry and patent protection for

TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript

TG Therapeutics (TGTX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.39 per share a year ago.

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance

Shares of TG Therapeutics Inc (NASDAQ: TGTX) opened 11% up on Wednesday after the biopharmaceutical firm said it sees a meaningful increase in its revenue from Briumvi this year. TG Therapeutics issue

TG Therapeutics Inc.'s stock TGTX, -1.36% rallied 11% early Wednesday, after the biotech said it's entered an agreement with microcap Precision BioSciencies Inc. DTIL, +10.10% to acquire a worldwide l

TG Therapeutics (NASDAQ: TGTX) stock price continued its recovery after the company published strong financial results. The shares jumped to the psychologically important level of $15, its highest poi

TG Therapeutics' Q3'23 net sales of Briumvi of $25.1M seemed to impress the market. Q3'23 sales of Briumvi were aided by J-code availability and increases in payor coverage. Q4'23 sales are hard to pr

The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, t

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - C